FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average	burden					
nours per response	e 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person * Newell Joe					2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 05/18/2020								X Officer (give title below) Other (specify below) Chief Operations Officer						
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)									6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City	')	(State)	(Zip)			Ta	able I	- Nor	ı-Der	ivative	Securiti	ies Ac	cquir	ed, Dispo	sed of, or I	Beneficially	Owned		
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Exect any	•	Code (Instr. 8)			4. Securities Acquired (A) or Disposed of (I) (Instr. 3, 4 and 5)		D) Beneficia Reported		nt of Securities ally Owned Following I Transaction(s)		6. Ownership Form:	Beneficial			
				(Month/Day/Year)			ode	V	Amoun	(A) or (D)	Prio		(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)		
Common	Stock		05/18/2020				S ^t	(1)		1,603	D	\$ 11.2 (2)	22	123,881			D		
	report on u	Sparate Inte 1	or each class of secu	Deriva	ative Se	curit	ies Ac	equire	Pers cont the f	ons whatained ifform dis	no resp n this t splays of, or B	form a cu Benefi	are rren cially	not requ tly valid		ormation spond unle rol numbe	ss	1474 (9-02)	
	2. Conversion or Exercise Price of Derivative Security	(Month/Day	n 3A. Deemed Execution Da any	4. Transaction Code Year) (Instr. 8)		5.		and Expiration Date (Month/Day/Year) Au Un Se (In			7. Tit Amou Unde Secur (Instr	le and unt of rlying rities . 3 and	Derivative Security (Instr. 5)	9. Number o Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	Benefici Ownersh (Instr. 4)			
					Code	V	(A)	(D)	Date Exer		Expirat Date	tion	Γitle	Amount or Number of Shares					

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Newell Joe C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080			Chief Operations Officer					

Signatures

/s/ David Tucker, Attorney-in-Fact for Joe Newell	05/20/2020
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.
- (2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2020 and May 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.